Market Overview:
The global organ-on-chip market size reached US$ 47.0 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 266.0 Million by 2028, exhibiting a growth rate (CAGR) of 31.1% during 2023-2028.
Organ-on-chip refers to a microfluidic cell culture device utilized in effective drug discovery of precision medicine and a fast-track prospect of tissue engineering. It helps develop a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, and heart. It enables the creation of a specific human model with functional responses at the organ or tissue level to avoid the usage of animal models. Apart from this, it offers several advantages, such as efficient fluid flow, relevant mechanical cues, an organ-level tissue-tissue interface, and separate access to parenchymal and vascular compartments.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Organ-on-chip Market Trends:
There is a currently rise in the demand for organ-on-chips in drug screening to reduce employee healthcare costs; improve employee morale, productivity and performance; and decrease absenteeism, accidents, downtime, turnover, and theft. This, along with the growing demand for lung and kidney-based organ culture devices, represents one of the key factors driving the market. Moreover, there is an increase in the availability of laboratory-engineered functional organs across the globe. This, coupled with the escalating demand for an alternative to animal testing through research activities on organ-on-chip devices for new drug development, is propelling the growth of the market. In addition, the rising adoption of organ-on-chips technology due to advancements in cell biology, microfabrication, and microfluidics is offering lucrative growth opportunities to industry investors. Besides this, the increasing application of organ-on-chips devices in the healthcare industry for real-time imaging, in vitro analysis of biochemical, and genetic and metabolic activities of living cells in a functional tissue are positively influencing the market. Apart from this, key market players are extensively investing in research and development (R&D) activities to develop new solutions and treat pulmonary diseases, which is catalyzing the demand for organ-on-chips technology.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global organ-on-chip market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on offering, type, application and end use.
Breakup by Offering:
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Breakup by Type:
- Liver
- Heart
- Lung
- Kidney
- Others
Breakup by Application:
- Physiological Model Development
- Drug Discovery
- Toxicology Research
Breakup by End Use:
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Cosmetics Industry
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Allevi Inc., Altis Biosystems, AxoSim, BiomimX S.r.l., Elveflow, Emulate Inc., InSphero, MIMETAS, Nortis Inc., TARA Biosystems Inc. and TissUse GmbH.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Million |
Segment Coverage |
Offering, Type, Application, End Use, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Allevi Inc., Altis Biosystems, AxoSim, BiomimX S.r.l., Elveflow, Emulate Inc., InSphero, MIMETAS, Nortis Inc., TARA Biosystems Inc. and TissUse GmbH. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |